Nanmo Bio: Net profit of 32.4313 million yuan in 2025, a year-on-year increase of 399.29%

Nanmo Biotech Releases Earnings Briefing, Achieving Operating Revenue of 421 million yuan in 2025, a year-on-year increase of 10.50%; net profit of 32.43 million yuan, a year-on-year increase of 399.29%. During the reporting period, signs of recovery appeared in China’s biopharmaceutical industry, with the company’s industrial revenue increasing compared to the same period last year. The company continued to strengthen cost control and improve operational efficiency through measures such as adjusting cage layout, controlling procurement prices, and optimizing business processes, further reducing costs and expenses. Meanwhile, non-recurring income such as government subsidies increased year-on-year.